

Table of Contents



Over 1,000 corporations in 70 countries are relying on our market intelligence, expert analysis, and strategic insight, critical to the development and implementation of effective business, R&D and marketing programs.

www.LeadingMarketResearch.com

www.VPGMarketResearch.com

reports@vpgcorp.com

+1 212 564 2838

Table of Contents

I. Introduction

II. Worldwide Market Overview

III. Major Product Development Opportunities

- A. Reagent Kits and Test Systems/Panels
- B. Instrumentation
- C. Computers, Software and Automation
- D. Auxiliary Products

IV. Design Criteria for Decentralized Testing Products

V. Alternative Market Penetration Strategies

- A. Internal Development
- B. Collaborative Arrangements
- C. University Contracts
- D. Distribution Strategies

VI. Potential Market Entry Barriers and Risks

- A. Market Maturity
- B. Cost Containment
- C. Competition
- D. Technological Edge and Limitations
- E. Patent Protection
- F. Regulatory Constraints
- G. Decentralized Testing Market Challenges

VII. Worldwide Market and Technology Overview

A. Breast Cancer Statistics and Etiology

B. Breast Cancer Diagnostic Tests

1. CEA
2. CA 15-3
3. CA 27.29
4. CA 125
5. Estrogen Receptor
6. HER2
7. Polypeptide-Specific Antigen
8. Progesterone Receptor

Table of Contents (continued)

C. Cancer Diagnostic Testing Instrumentation Review and Market Needs

D. Current and Emerging Cancer Diagnostic Technologies

1. Monoclonal and Polyclonal Antibodies
2. Immunoassays
3. Molecular Diagnostics
4. Chromosome Analysis
 - a. Chronic Myelogenous Leukemia (CML)
 - b. Acute Myeloid Leukemia (AML)
 - c. Acute Lymphoblastic Leukemia (ALL)
 - d. Malignant Lymphomas Lymphoid Malignancies
 - e. Chronic Lymphocytic Leukemia (CLL)
 - f. Solid Cancers
 - g. Chromosomal Translocation and Oncogenes
5. Artificial Intelligence
6. Flow Cytometry
7. Two Dimensional Gel Electrophoresis (2-DGE)
8. Biosensors
9. Competing/Complementing Technologies

E. Personal Testing

VIII. Country Market Analyses: Breast Cancer Diagnostics Market Test Volume and Sales Forecasts for 92 Countries:

Albania, Argentina, Australia, Austria, Bahrain, Bangladesh, Belarus, Belgium, Bolivia, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Cuba, Cyprus, Czech Republic, Denmark, Dominican Republic, Ecuador, El Salvador, Estonia, Finland, France, Georgia, Germany, Greece, Guatemala, Haiti, Honduras, Hong Kong, Hungary, Iceland, India, Indonesia, Iran, Iraq, Ireland, Israel, Italy, Jamaica, Japan, Jordan, Kazakhstan, Kuwait, Latvia, Lebanon, Lithuania, Malaysia, Malta, Mexico, Moldova, Myanmar, Netherlands, New Zealand, Nicaragua, Norway, Oman, Pakistan, Panama, Paraguay, Peru, Philippines, Poland, Portugal, Puerto Rico, Qatar, Romania, Russia, Saudi Arabia, Serbia, Singapore, Slovak Republic, Slovenia, South Korea, Spain, Sweden, Switzerland, Taiwan, Thailand, Turkey, UK, Ukraine, United Arab Emirates, Uruguay, USA, Venezuela, Vietnam

Table of Contents (continued)

IX. Competitive Profiles

The report provides strategic assessments of over 30 cancer diagnostics market players and start-up companies with innovative technologies and products, including:

- Abbott
- Affymetrix
- Becton Dickinson
- bioMerieux
- Bio-Rad
- Danaher/Beckman Coulter/Cepheid
- DiaSorin
- Eiken Chemical
- Elitech Group
- Enzo Biochem
- Fujifilm Wako
- Fujirebio
- Grifols
- Hologic
- Leica Biosystems
- Qiagen
- QuidelOrtho
- Roche
- Siemens Healthineers
- Takara Bio
- Thermo Fisher